智通财经网·2026-03-06 07:21Core Insights - The biotechnology sector remains one of the most focused themes in the global investment market, with strong growth momentum reflected in the performance of related stocks and the overall sector [1] - The Hang Seng Biotechnology Index, launched in 2019, tracks 30 of the largest biotechnology companies listed in Hong Kong and has seen a significant increase of 64.5% in 2025, with an additional rise of 10.7% year-to-date as of February 24, 2026 [1] Group 1: Market Performance - The Hang Seng Biotechnology Index has a weight distribution of approximately 50% for biotechnology companies and 40% for pharmaceutical companies, with additional representation from drug distribution (6%) and medical devices (4%) [1] - The number of biotechnology and healthcare companies listed in Hong Kong has exceeded 270, with a total market capitalization of over HKD 4.2 trillion, showing substantial growth since the end of 2018 [2] Group 2: Investment Tools - The Hong Kong Stock Exchange offers a diverse range of investment and risk management tools in the biotechnology sector, including stocks, ETFs, structured products, and derivatives [2] - As of the end of February 2026, there are 10 ETFs tracking the Hang Seng Biotechnology Index, with a total asset management scale of HKD 15.6 billion, and the number of structured products linked to biotechnology stocks has increased from 132 in January 2025 to 500 in January 2026 [2] Group 3: Derivative Instruments - The introduction of the Hang Seng Biotechnology Index futures in November 2025 provides investors with more options for participation and risk management in the biotechnology sector [3] - Each futures contract has a contract multiplier of HKD 50 per index point, meaning a 100-point change in the index results in a contract value change of HKD 5,000 [3] Group 4: Volatility and Risk Management - The annualized volatility of the Hang Seng Biotechnology Index was approximately 41.2% for the 12 months ending January 2026, significantly higher than the Hang Seng Index (24.2%) and the Hang Seng China Enterprises Index (25.9%) [4] - Investors can use the Hang Seng Biotechnology Index futures in conjunction with biotechnology ETFs or stocks to manage overall sector risk, allowing for hedging while maintaining long-term positions [4]